Levodopa motor complications in Parkinson's disease

Trends in Neurosciences

Volumn 23, Issue 10 SUPPL., 2000, Pages

  Obeso, José A ^a   Olanow, C Warren ^b   Nutt, John G ^c  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

AKINESIA; DYSKINESIA; HEALTH CARE COST; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RIGIDITY; TREMOR; UNITED STATES;

EID: 0033695441     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-1931(00)00031-8     Document Type: Editorial

References (61)

1. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines (American Academy of Neurology)
2. The pathology of parkinsonism
3. Uneven pattern of dopamine loss in the striatum of patients with Parkinson's disease
4. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions
5. Aromatic aminoacids and modification of parkinsonism
6. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases
7. Success and problems of long-term levodopa therapy in Parkinson's disease
8. Motor complications associated with chronic levodopa therapy in Parkinson's disease
9. Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
10. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease
11. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: A target for neuroprotection
12. A radical hypothesis for neurodegeneration
13. Cell death and neuroprotection in Parkinson's disease
14. Subthalamic deep brain stimulation
15. Surgery for Parkinson's disease: A physician's perspective
16. Preventing levodopa-induced dyskinesias
17. Risk factors for levodopa-induced dyskinesias in Parkinson's disease
18. Motor fluctuations in Parkinson's disease: Pathophysiology and treatment
19. Fluctuations of disability in Parkinson's disease: Clinical aspects
20. Fluctuations of disability in Parkinson's disease: Pathophysiology
21. Young onset Parkinson's disease
22. Levodopa-induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification
23. Levodopa-induced dyskinesias in Parkinson's disease: Phenomenology and pathophysiology
24. Patterns of dystonia ('I-D-I' and 'D-I-D') in response to L-dopa therapy for Parkinson's disease
25. The spectrum of levodopa-induced dyskinesias
26. Long-term side effects of levodopa
27. 3 H]spiperone binding
28. Chronic parkinsonism in humans due to a product of meperidine analog synthesis
29. The response to levodopa in Parkinson's disease: Imposing pharmacological law and order
30. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a 4 year period
31. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease
32. Effect of long-term therapy on the pharmaco-dynamics of levodopa. Relation to on-off phenomenon
33. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease
34. Motor fluctuations in Parkinson's disease: Pathogenetic and therapeutic studies
35. Fluctuation in response to chronic levodopa therapy: Pathogenetic and therapeutic considerations
36. Motor fluctuations in levodopa-treated Parkinsonian rats: Relation to lesion extent and treatment duration
37. Rationale for continuous dopaminomimetic therapy of Parkinson's disease
38. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease
39. Difference in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease
40. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: Implications for the pathogenesis of the on-off phenomenon
41. Wearing-off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms
42. Apomorphine can sustain the long-duration response to L-DOPA in fluctuating Parkinson's disease
43. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease
44. Deep brain stimulation changes the magnitude of the motor response to levodopa in Parkinson's disease: Pathophysiological implications
45. Levodopa-induced dyskinesias in Parkinson's disease: Is sensitization reversible?
46. Posteroventral medial pallidotomy in advanced Parkinson's disease
47. A hypothesis on the pathophysiological mechanisms that underlie levodopa or dopamine agonist-induced dyskinesia in Parkinson's disease
48. Primate models of movement disorders of basal ganglia origin
49. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: Problems with the current model
50. Molecular basis of levodopa-induced dyskinesias
51. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease
52. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease
53. Dopamine-mediated gene regulation in models of Parkinson's disease
54. Striatal mechanisms and pathogenesis of parkinsonian signs
55. The corticostriatal projection: From synaptic plasticity to dysfunctions of the basal ganglia
56. Factors influencing the onset and persistence of dyskinesias in the Parkinsonian primate
57. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat
58. Continuous dopaminergic stimulation for Parkinson's disease
59. Continuous dopaminergic-receptor stimulation in early Parkinson's disease
60. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group